Skip to content
drillr.ai
Sign up

600276.SH

恒瑞医药

SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN

CNY 46.76
−2.05%
Ask drillr

  • Sep 3, 2026, 09:01 UTC

    Hengrui Medicine announced that its subsidiary Guangdong Hengrui Medicine received an acceptance notice from China's National Medical Products Administration for the marketing authorization application of its self-developed drug Zhuotuoqibei monoclonal antibody injection (SHR-1819), intended for treating moderate-to-severe atopic dermatitis in adults.

    Source:

  • Sep 2, 2026, 08:40 UTC

    Hengrui Medicine's subsidiary Shandong Shengdi Pharmaceutical received acceptance from China's National Medical Products Administration for the marketing authorization application of HRS-7535 tablets, a novel oral small-molecule GLP-1R agonist for type 2 diabetes.

    Source:

  • Aug 31, 2026, 08:47 UTC

    Hengrui Pharmaceuticals announced that its subsidiary Suzhou Shengdiya Biopharmaceutical's ADC drug Ruikang trastuzumab (SHR-A1811) met the primary endpoint in a Phase III clinical trial for first-line treatment of HER2-positive advanced breast cancer, and the company plans to submit a pre-marketing communication application to the CDE.

    Source:

  • Aug 26, 2026, 10:33 UTC

    JPMorgan Chase increased its long position in Jiangsu Hengrui Pharmaceuticals H shares from 9.59% to 10.69% on August 21, as disclosed by the Hong Kong Stock Exchange.

    Source:

  • Aug 25, 2026, 09:06 UTC

    GIC Private Limited increased its stake in Hengrui Medicine's H shares from 14.29% to 15.70% on August 20, 2026, with an average purchase price of HKD 50.5655 per share.

    Source:

  • Aug 24, 2026, 09:01 UTC

    Hengrui Medicine announced that its self-developed Class 2 new drug HRG2010 capsule, intended for Parkinson's disease, has had its marketing authorization application accepted by China's National Medical Products Administration.

    Source:

  • Aug 20, 2026, 12:58 UTC

    Hengrui Medicine's subsidiary Beijing Shengdi received approval from China's National Medical Products Administration to conduct clinical trials for its SHR-8203 injection as monotherapy in advanced solid tumors.

    Source:

  • Aug 19, 2026, 11:39 UTC

    Hengrui Medicine announced its first-half 2026 results with revenue of 15.456 billion yuan, down 1.94% year-on-year, and net profit attributable to shareholders of 4.465 billion yuan, up 0.34%.

    Source:

  • Aug 14, 2026, 10:25 UTC

    Hengrui Medicine repurchased 488,000 A-shares for 25.8 million yuan on August 14, 2026, for its employee stock ownership plan.

    Source:

  • Aug 13, 2026, 09:39 UTC

    Hengrui Medicine repurchased 405,000 A-shares for 21.86 million yuan on August 13, 2026, for its employee stock ownership plan.

    Source:

  • Aug 10, 2026, 09:40 UTC

    Hengrui Medicine repurchased 200,000 A-shares for 10.7833 million yuan on August 10, 2026, via centralized bidding for its employee stock ownership plan.

    Source:

  • Aug 6, 2026, 09:18 UTC

    Hengrui Medicine announced that on August 6, 2026, it repurchased 985,800 A-shares for its employee stock ownership plan through the Shanghai Stock Exchange, at a total cost of approximately 51.86 million yuan, with the highest and lowest repurchase prices per share being 52.91 yuan and 52.01 yuan respectively.

    Source:

  • Aug 4, 2026, 08:49 UTC

    Hengrui Medicine announced that in July 2026 it repurchased 280,000 A-shares as treasury stock at 53.89 yuan per share, bringing total treasury shares to 8.5905 million.

    Source:

  • Jul 31, 2026, 09:11 UTC

    Capital Group increased its stake in Hengrui Medicine H-shares on July 29, raising its holding from 9.86% to 10.04%, with an average purchase price of 57.9041 HKD.

    Source:

  • Jul 30, 2026, 01:42 UTC

    China's National Medical Products Administration approved four innovative drugs for market launch.

    Source:

  • Jul 28, 2026, 07:25 UTC

    Jiangsu Hengrui Medicine Co., Ltd. established a wholly-owned subsidiary Zhejiang Hengrui Medicine Co., Ltd. in Zhejiang with a registered capital of 50 million yuan.

    Source:

  • Jul 28, 2026, 02:02 UTC

    CSPC Pharmaceutical Group's marketing application for injectable sirolimus (albumin-bound) was accepted by the National Medical Products Administration and granted priority review.

    Source:

  • Jul 28, 2026, 01:36 UTC

    Ascletis Pharma announced that its once-monthly subcutaneous triple agonist peptide ASC37 showed superior weight loss effects in a diet-induced obesity mouse model.

    Source:

  • Jun 5, 2026, 23:32 UTC

    Hengrui Pharma and Kailera Therapeutics presented clinical data for ribupatide at the ADA 2026 conference.

    Source:

  • Jun 1, 2026, 06:00 UTC

    Hengrui Pharma presented more than 90 oncology studies at ASCO 2026, highlighting progress across multiple tumor types.

    Source: